Oligonucleotide synthesis is the chemical synthesis of relatively small fragments of nucleic acids with a defined chemical structure (sequence). The technique is extremely useful in current laboratory practice as it provides a rapid and inexpensive access to custom-made oligonucleotides of the desired sequence. It is also useful for performing molecular diagnostics in many diseases, including the detection of infectious diseases, such as Hepatitis, SARS-CoV2, as well as for cancer diagnosis.

Increased government support for synthetic biology and genome projects and robust research is a major factor driving the growth of the oligonucleotide synthesis market. Furthermore, R&D spending in pharmaceutical and biotechnology companies to produce oligonucleotide products with enhanced therapeutic potential and fewer side effects is further fueling the market growth. Furthermore, the increasing demand for high-end customized oligos and upgrades in the purification of synthetic oligonucleotides along with the increasing applications of synthesized oligonucleotides in molecular diagnostics and clinical applications are also fueling the growth of the oligonucleotide synthesis market. In contrast, the market for oligonucleotide synthesis may be hindered by the complexities associated with therapeutic oligos and the challenging delivery of oligonucleotide drugs to specific targets. However, the growth opportunities in emerging economies and the focus on personalized medicine predict lucrative increasing research and development activities in the fields of genomics and genetics.

Growth Drivers:

  • Expansion of manufacturing facilities by market players
  • Increasing research and development activities in the field of genomics and genetics

Restraints & Challenges:

  • Oligo-degradation in generic testing
  • Low quality generated oligonucleotide sequences of the microarray

Global Oligonucleotide Synthesis Market: Restraints

Natural oligonucleotides are composed of ribose or deoxyribose sugar phosphate as a base, which are quickly destroyed by the nucleus in the body. Also in generic testing, oligo-degradation can affect cell growth and cell proliferation. Furthermore, the low quality of the microarray generated oligonucleotide sequence is a major challenge in the adoption of microarray technology for oligonucleotide synthesis. These factors are expected to restrain the growth of the global oligonucleotide synthesis market.

Global Oligonucleotide Synthesis Market – Impact of Coronavirus (COVID-19) Pandemic

The outbreak of the coronavirus disease (COVID-19) was first recorded on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2020.

According to the Coronavirus Disease (COVID-19) weekly epidemiological update by the World Health Organisation, more than 61.8 million cases and 1.4 million deaths due to the coronavirus disease (COVID-19) have been registered worldwide as of November 29, 2020.

To combat the COVID-19 pandemic, market players and government officials are collaborating to explore oligonucleotide platforms for the development of COVID-19 treatments. For example, on April 28, 2020, Sarepta Therapeutics, Inc., and the U.S. The Army Medical Research Institute of Infectious Diseases (USAMRIID), a Department of Defense’s premier laboratory for medical biological defense research, entered into a Cooperative Research and Development Agreement (CRADA). To identify antisense oligonucleotides against SARS-CoV-2 for potential treatment of COVID-19.

For more information about this report https://www.factmr.com/report/4853/oligonucleotide-synthesis-market

Contact Us:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: [email protected]

Website: https://www.factmr.com